TrueMark Investments LLC Raises Stock Position in The Clorox Company (NYSE:CLX)

TrueMark Investments LLC increased its position in The Clorox Company (NYSE:CLX - Free Report) by 8.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,702 shares of the company's stock after purchasing an additional 2,993 shares during the period. Clorox makes up 1.4% of TrueMark Investments LLC's investment portfolio, making the stock its 17th largest holding. TrueMark Investments LLC's holdings in Clorox were worth $5,404,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Clorox by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock worth $2,518,517,000 after purchasing an additional 124,428 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Clorox by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock worth $501,925,000 after purchasing an additional 69,969 shares in the last quarter. Stifel Financial Corp lifted its stake in Clorox by 0.4% during the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock valued at $380,761,000 after acquiring an additional 9,582 shares in the last quarter. Norges Bank bought a new position in Clorox during the 4th quarter valued at $259,041,000. Finally, Northern Trust Corp lifted its stake in Clorox by 18.2% during the 4th quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock valued at $242,684,000 after acquiring an additional 230,173 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group dropped their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday. Barclays dropped their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research note on Wednesday, May 7th. Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a research note on Tuesday, May 6th. Morgan Stanley dropped their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Clorox presently has a consensus rating of "Hold" and a consensus target price of $149.50.

Clorox Stock Performance

Shares of Clorox stock traded down $1.45 during trading hours on Thursday, hitting $118.03. 1,829,014 shares of the company's stock traded hands, compared to its average volume of 1,368,834. The Clorox Company has a 12-month low of $117.38 and a 12-month high of $171.37. The stock has a market capitalization of $14.55 billion, a price-to-earnings ratio of 21.19, a PEG ratio of 2.70 and a beta of 0.54. The company has a fifty day simple moving average of $131.62 and a 200-day simple moving average of $145.61. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 9.89% and a return on equity of 324.23%. The business had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.74 billion. During the same period in the prior year, the business earned $1.71 earnings per share. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. Equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company's stock, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.57% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.